Costs were not discounted, the rationale being that costs relating to adjuvant intraportal chemotherapy were thought to occur exclusively during the first year of the patients' follow-up. Quantities and costs were given separately. Costs and quantities included were health care costs (drugs, medical equipment and administration). A health service perspective was adopted. Quantities and costs used were based on actual data. Whilst the resources data were obtained from the trial, the administration costs were derived from actual average costs recorded in the hospital to which the authors were attached. The resource use date was not given. 1996 price data were used. Only the costs of the drugs for the treatment group and the associated administration costs were included. Within the sensitivity analysis, allowance was made for the impact on costs of the possible waste of unused products in the administration of the adjuvant intraportal chemotherapy.